France Anti-Infective Agents Market Size & Outlook
- Pharmaceuticals
- Infectious Disease Treatment
- anti infective agents market
- Infectious Disease Treatment
Global Market
Related Markets
Ask a question about the anti infective agents market
France anti-infective agents market highlights
- The France anti-infective agents market generated a revenue of USD 4,801.6 million in 2025 and is expected to reach USD 5,419.7 million by 2033.
- The France market is expected to grow at a CAGR of 1.8% from 2026 to 2033.
- In terms of segment, antibacterials was the largest revenue generating type in 2025.
- Antifungals is the most lucrative type segment registering the fastest growth during the forecast period.
Anti-infective agents market data book summary
| Market revenue in 2025 | USD 4,801.6 million |
| Market revenue in 2033 | USD 5,419.7 million |
| Growth rate | 1.8% (CAGR from 2026 to 2033) |
| Largest segment | Antibacterials |
| Fastest growing segment | Antifungals |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antibacterials, Antivirals, Antifungals |
| Key market players worldwide | Pfizer Inc, Abbott Laboratories, Gilead Sciences Inc, Bristol-Myers Squibb Co, Merck & Co Inc, Sandoz Group AG ADR, B. Braun, Novo Holdings, Mankind Pharma, Bayer AG, AstraZeneca PLC, Boehringer Ingelheim Pharma |
Other key industry trends
- In terms of revenue, France accounted for 3.6% of the global anti-infective agents market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, UK anti-infective agents market is projected to lead the regional market in terms of revenue in 2033.
- UK is the fastest growing regional market in Europe and is projected to reach USD 9,148.0 million by 2033.
The anti-infective agents market in France is expanding, driven by collaborations between research institutions and companies to address infectious diseases and combat antimicrobial resistance. For instance, in March 2023, Nosopharm, a biotech firm focused on discovering antibiotics from unconventional sources, was selected for the French Tech Health20 program.
Additionally, in June 2022, Nosopharm announced the successful completion and positive results of toxicology studies for NOSO-502, a novel antibiotic designed to treat multidrug-resistant hospitalacquired infections.
No credit card required*
Publish Date: Jun 25, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti Infective Agents Market
Anti Infective Agents Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| B. Braun | View profile | 10001+ | Chapeltown, Sheffield, United Kingdom, Europe | www.bbraun.co.uk |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Gilead Sciences Inc | View profile | 18,000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | www.gilead.com |
| Mankind Pharma | View profile | 10001+ | New Delhi, Delhi, India, Asia | www.mankindpharma.com |
| Boehringer Ingelheim Pharma | View profile | 10001+ | Dortmund, Nordrhein-Westfalen, Germany, Europe | www.boehringer-ingelheim.de/unternehmensprofil/unser-unternehmen/standort-dortmund |
France anti infective agents market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Anti-infective Agents Market Outlook will help companies and investors design strategic landscapes.
Antibacterials was the largest segment with a revenue share of 46.17% in 2025.
Horizon Databook has segmented the France anti-infective agents market based on antibacterials, antivirals, antifungals covering the revenue growth of each sub-segment from 2021 to 2033.
The anti-infective agents market in France is expanding, driven by collaborations between research institutions and companies to address infectious diseases and combat antimicrobial resistance. For instance, in March 2023, Nosopharm, a biotech firm focused on discovering antibiotics from unconventional sources, was selected for the French Tech Health20 program.
Additionally, in June 2022, Nosopharm announced the successful completion and positive results of toxicology studies for NOSO-502, a novel antibiotic designed to treat multidrug-resistant hospitalacquired infections.
- France Anti-Infective Agents Market Type Outlook (Revenue, USD Million , 2021-2033)
- Antibacterials
- Antivirals
- Antifungals
- France Anti-Infective Agents Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Oral
- Parenteral
- Topical
- Others
- France Anti-Infective Agents Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Reasons to subscribe to anti infective agents market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of anti infective agents market databook
- Our clientele includes a mix of anti infective agents market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France anti infective agents market, including forecasts for subscribers. This country databook contains high-level insights into France anti infective agents market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
France Anti-Infective Agents Market, 2021-2033 (US$M)
France Type - Anti-infective Agents Market Statistics, 2025 - 2033 (US$M)
